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Objective: High levels of toxic reactive oxygen species have been found in many types of cancer cells.
Serum arylesterase (ARE) and paraoxonase (PON) are esterase enzymes that have strong antioxidant
characteristics. The main purpose of our study was to evaluate the activity of ARE and PON in the sera of
patients with ovarian cancer and benign ovarian tumors.
Materials and methods: This study included 30 patients with ovarian cancer, 42 patients with benign
ovarian tumors, and 19 healthy age- and sex-matched individuals. ARE and PON activities were measured
using spectrophotometry.
Results: Serum ARE activity was signiﬁcantly different among the three studied groups (p< 0.0001).
However, posthoc tests revealed that ARE activity was lower in the benign ovarian tumor group (median,
1.53 U/mL; range, 0.43e2.47 U/mL) than in the other groups. There were no differences in ARE activity
between patients with ovarian cancer (1.89 U/mL; range, 1.01e2.56 U/mL) and healthy individuals
(2.05 U/mL; range, 0.79e2.44 U/mL). We found no differences in PON activity or the PON:ARE activity
ratio between the studied groups. Tumor size in the benign ovarian tumor group was positively corre-
lated with ARE activity (R Spearman¼ 0.46, p¼ 0.003) and negatively correlated with PON activity (R
Spearman¼0.50, p¼ 0.001). The ARE and PON activities were not inﬂuenced by histological type,
ovarian cancer grade, or disease advancement.
Conclusion: ARE activity is higher in patients with ovarian cancer than in patients with benign ovarian
tumors; however, the serum activity of ARE is similar between patients with cancer and healthy
individuals.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Epithelial ovarian cancer is the most lethal gynecologic malig-
nancy and the ﬁfth leading cause of cancer-related death among
women in the USA. The lifetime risk of developing ovarian cancer is
estimated to be 1.3%, while the 5-year survival rate is approxi-
mately 44.6%. The survival rate is strictly related to disease stage at
the time of diagnosis. If ovarian cancer is conﬁned to the primary
site, the 5-year relative survival is near 92.3%. Unfortunately, only
about 15% of ovarian cancer cases are diagnosed before the diseaseurgery, Poznan University of
land.
bstetrics & Gynecology. Publishedhas spread [1]. This is mainly due to the lack of early speciﬁc
symptoms and screening tests.
Oxidative stress is an imbalance between toxic reactive species
[reactive oxygen species (ROS) and reactive nitrogen species (RNS)]
and antioxidative defense mechanisms [2], and carcinogenesis is
correlated with excessive oxidative stress [3]. Antioxidants and
antioxidant enzymes play the main roles in the antioxidative de-
fense mechanism. Arylesterase (ARE) and paraoxonase (PON),
different activities of the same enzyme, are serum esterases with
strong antioxidant characteristics [4]. Physiologically, PON circu-
lates in the serum in association with high-density lipoprotein and
protects low-density lipoproteins against oxidation [5]. Both PON
and ARE interact and play a role in the plasma antioxidant system.
Disturbances in their activity have been shown to be implicated in
several morbidities, especially cerebrovascular diseases [6]. AREby Elsevier Taiwan LLC. All rights reserved.
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[7,8].
The main aim of this study was to determine the serum ARE and
PON activities in patients diagnosed with ovarian cancer and pa-
tients with benign ovarian tumors. Enzyme activities in both
groups were compared with the esterase activities of healthy
controls. ARE and PON activities were evaluated according to
various disease characteristics.
Materials and methods
Serum samples were collected from 72 patients treated in the
Division of Gynecological Surgery, Poznan University of Medical
Sciences, Poznan, Poland in 2009e2012 and from 19 healthy
women. Gynecological and ultrasonographic examinations were
conducted 1e3 days prior to surgical treatment during the ﬁrst 10
days of each participant’s menstrual cycle. The studied patients
were divided into the following three groups: (1) those with ma-
lignant ovarian tumors (n¼ 30); (2) those with benign ovarian tu-
mors (n¼ 42); and (3) healthy women (n¼ 19). The histological
types of the tumors analyzed are presented in Table 1. All patients
and healthy volunteers were age-matched. Moreover, there were
no differences in the patients’ body mass index (BMI) and meno-
pausal status. The characteristics of the patients and healthy con-
trols are shown in Table 2.
According to the International Federation of Gynecology and
Obstetrics (FIGO) classiﬁcation, therewere ﬁve patients with Stage I
disease, six patients with Stage II disease, 13 patients with Stage III
disease, and six patients with Stage IV disease. The majority of
patients (16 women) were diagnosed with histological Grade 3,
seven had patients had Grade 2, and six patients had Grade 1
ovarian cancer. Serum samples were obtained within 3 days prior
to the operation. PON and ARE activities in the sera were estimated
by spectrophotometric method with the use of paraoxon and
phenyl acetate as substrates, respectively, according to previously
described methods [3,9].
The ARE and PON activities as well as the PON:ARE activity ra-
tios in the patients’ sera were compared among the three studied
groups. Serum esterase activities were correlated with the histo-
logical type of the tumors, tumor volume (estimated using preop-
erative ultrasonographic examination), patient age, and patient
BMI. ARE and PON activities were correlated with the FIGO stage of
the disease and tumor histological grade in the group of patients
with ovarian cancer.
The study received approval from the local ethics committee.
Results
Serum ARE activities were signiﬁcantly different among the 3
studied groups (p< 0.0001). Median ARE activity assessed in theTable 1
Histopathological ﬁndings among the studied patients.
Benign ovarian tumors (n¼ 42)
Endometrioid cysts 14
Serous cystadenoma 8
Mucinous cystadenoma 5
Mature teratoma 5
Other 6
Persistent functional ovarian cysts 4
Ovarian cancers (n¼ 30)
Serous adenocarcinoma 13
Mucinous adenocarcinoma 4
Clear cell adenocarcinoma 3
Endometrioid adenocarcinoma 3
Undifferentiated carcinoma 5
Other 2sera of patients with ovarian cancer was 1.89 U/mL (range,
1.01e2.56 U/mL). For comparison, median ARE activity in the sera
of patients with benign ovarian tumors and the healthy controls
were 1.53 U/mL (range, 0.43e2.47 U/mL) and 2.05 U/mL (range,
0.79e2.44 U/mL), respectively. Posthoc testing revealed statistically
signiﬁcant differences in ARE activities between the ovarian cancer
and benign ovarian tumor groups (p< 0.01) as well as between the
benign ovarian tumor and healthy control groups (p< 0.001).
However, there were no differences between themalignant ovarian
tumor and healthy groups (p> 0.05).
There were no differences in PON activity among the studied
groups (p¼ 0.38). Median serum PON activity in the ovarian cancer
group was 50.31 U/mL (range, 8.4e268.3 U/mL), while the median
PON activities in the benign ovarian tumor and healthy control
groups were 71.6 U/mL (range, 0e430.1 U/mL) and 77.6 U/mL
(range, 15.1e307.7 U/mL), respectively. Similarly, there was no
statistically signiﬁcant difference in the PON:ARE activity ratio
among the studied groups (p¼ 0.24). Median PON:ARE activity
ratios in the ovarian cancer, benign ovarian tumor, and healthy
control groups were 30.1 (range, 3.28e183.5), 55.00 (range,
8.51e1000.2), and 43.53 (range, 6.51e389.49), respectively. The
esterase activity measurements are shown in Table 3.
We evaluated the activities of esterases in relation to tumor size
within the benign andmalignant ovarian tumor groups and found a
signiﬁcant positive correlation between ARE activity and tumor size
in the benign ovarian tumor group (R Spearman¼ 0.46, p¼ 0.003).
On the contrary, no correlation was noted between tumor size and
ARE activity in the ovarian cancer group (R Spearman¼ 0.13,
p¼ 0.324). There was a statistically signiﬁcant negative correlation
between PON activity and tumor size in the benign ovarian tumor
group (R Spearman¼0.50, p¼ 0.001), but there was no correla-
tion between tumor size and PON activity in the ovarian cancer
group (R Spearman¼ 0.132, p¼ 0.55). The PON:ARE ratio was also
negatively correlated with tumor size in the benign ovarian tumor
group (R Spearman¼0.45, p¼ 0.039) but not correlated with
tumor size in the ovarian cancer group (R Spearman¼ 0.035,
p¼ 0.87). We found no differences in ARE and PON activities or
PON:ARE ratio according to the histological types of the tumors.
Mean ARE activity in the sera of patients with early stage ovarian
cancer (I and II according to FIGO) was 2.02± 0.34 U/mL, which was
not signiﬁcantly different from the ARE activity in patients with
advanced ovarian cancer stage assessed as III or IV according to FIGO
(range, 1.92± 0.44 U/mL, p¼ 0.63). Similarly, there were no
statistically relevant differences in PON activity among these
groups of patients (p¼ 0.45). Median PON activity in early stage
ovarian cancer was 76.3 U/mL (range, 25.2e268.3 U/mL), while
median PON activity in the sera of patients with advanced stage
ovarian cancer was 41.08 U/mL (range, 8.4e219.69 U/mL). The dif-
ference inPON:ARE ratio betweenpatientswithearly stage (median,
32.85; range, 11.45e183.5) and advanced stage (median, 20.99;
range, 3.28e155.81) ovarian cancer was not signiﬁcant (p¼ 0.747).
Moreover, no differences were found between ARE activities,
PON activities, and PON:ARE activity ratios according to the histo-
logical grade of ovarian cancer (p¼ 0.33, p¼ 0.73, and p¼ 0.60,
respectively).
Serum ARE activity was positively correlated with patient age in
the benign ovarian tumor group (R Pearson¼ 0.4, p¼ 0.009). By
contrast, there was no correlation between age and ARE activity in
the group of patients with ovarian cancer (R Pearson¼0.22,
p¼ 0.25). Similarly, there was a negative correlation between PON
activity and patient age in the benign ovarian tumor group (R
Pearson¼0.34, p¼ 0.02), but there was no correlation in the
ovarian cancer group (R Pearson¼ 0.23, p¼ 0.22). ARE and PON
activities were not related to patient BMI in either the ovarian
cancer or the benign ovarian tumor group.
Table 2
Demographic characteristics of the studied patients.
Ovarian cancer
(n¼ 30)
Benign ovarian
tumors (n¼ 42)
Healthy controls
(n¼ 19)
p
Patient age (y), mean± SD 51.7± 11.3 47.8± 10.1 51.9± 8.2 0.19
Body mass index (kg/m2),
mean± SD
26.0± 5.9 24.9± 3.9 24.4± 4.1 0.77
Menopausal status Premenopausal, n (%) 14 (46.7%) 27 (64.3%) 7 (36.8%) 0.17
Postmenopausal, n (%) 16 (53.3%) 15 (35.7) 12 (63.2%)
SD¼ standard deviation.
Table 3
Arylesterase (ARE) and paraoxonase (PON) activities and PON:ARE ratio among the studied group of patients and the healthy individuals.
Ovarian cancer group
(n¼ 30)
Benign ovarian tumor
group (n¼ 42)
Healthy control group
(n¼ 19)
p
ARE activity (U/mL), median (range) 1.89 (1.01e2.56) 1.53 (0.43e2.47) 2.05 (0.79e2.44) <0.0001
PON activity (U/mL), median (range) 50.31 (8.4e268.3) 71.6 (0e430.1) 77.6 (15.1e307.7) 0.38
PON:ARE activity ratio, median (range) 30.1 (3.28e183.5) 55.00 (8.51e1000.2) 43.53 (6.51e389.49) 0.24
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The term “oxidative stress” characterizes the imbalance be-
tween the development of toxic reactive species (TRS) and anti-
oxidative defense mechanisms. TRS are subdivided into ROS and
RNS. ROS consists of superoxide anion (O2.), hydrogen peroxide
(H2O2), singlet oxygen (1O2), hydrogen superoxide (HO2$), and
especially, reactive hydroxyl radical (OH.). Nitric oxide (.NO) and
peroxynitrite (ONOO) are the most known among RNS [2,10]. ROS
can impair cellular lipids, proteins, and DNA, affecting enzyme ac-
tivity andmembrane function; thus, oxidative stress is considered a
tumor promoter. Moreover, cancer cells are characterized by
excessive ROS production. There are several sources of TRS in
cancer cells. Intensive metabolism and disturbances in the mito-
chondrial respiratory chain are considered major causes of ROS
production [11]. Furthermore, cancer tissue is inﬁltrated by acti-
vated macrophages that escalate the production of large amounts
of ROS and cytokines and heighten the inﬂammatory state [12].
Disorders in cellular signaling, such as activation of oncogenes like
RAS2 [13] or c-Myc [14], are also considered a substantial source of
ROS. Oxidative stress is potentially harmful for cells. However, in
the case of malignant neoplasms, intrinsic oxidative stress in cancer
cells may have dramatic consequences, such as cancer cell prolif-
eration, genetic instability promotion, and alterations in cellular
sensitivity to anticancer agents [15].
Ovarian cancer has been shown to be associated with oxidative
stress. Senthil et al [16] analyzed the concentrations of thio-
barbituric acid reactive substances and conjugated dienes, which
are considered markers of oxidative stress, as well as levels of an-
tioxidants such as superoxide dismutase, catalase, vitamin C, andTable 4
Comparison of the present study results with those of Camuzcuoglu et al [19].
Present study
ARE activity in ovarian cancer patients No different f
Higher than in
PON activity in ovarian cancer patients No different f
Benign ovaria
ARE activitydrelationship with stage of ovarian cancer No relationsh
PON activitydrelationship with stage of ovarian cancer No relationsh
ARE activitydrelationship with grade of ovarian cancer No relationsh
PON activitydrelationship with grade of ovarian cancer No relationsh
Percentage of advanced stage ovarian cancers 63.3%
ARE¼ arylesterase; PON¼ paraoxonase.vitamin E. The mentioned authors revealed signiﬁcantly elevated
thiobarbituric acid reactive substances and conjugated diene levels
and signiﬁcantly lowered levels of superoxide dismutase, catalase,
vitamin C, and vitamin E in patients with ovarian cancer compared
to those in healthy controls. ROS react with polyunsaturated fatty
acids, which leads to destruction of the cellular membrane by a
process called lipid peroxidation. Measurements of the concen-
trations of lipid and protein oxidation products are among the
objectives in the assessment of oxidative stress. Delimaris et al [17]
found that levels of oxidized low-density lipoproteins are signiﬁ-
cantly higher in patients with ovarian cancer than in healthy
controls.
Camuzcuoglu et al [18] compared ARE and PON activities among
patients with ovarian cancer and healthy controls. They found
signiﬁcantly lowered enzyme activities in the sera from patients
with ovarian cancer than in that from healthy individuals. These
ﬁndings are only partially consistent with our results. We also
revealed signiﬁcant differences in ARE activity among patients with
ovarian cancer, patients with benign ovarian tumors, and healthy
individuals. However, post hoc tests did not reveal any differences
between patients with ovarian cancer and healthy controls.
Furthermore, we found no differences in PON activities or PON:ARE
ratios among the studied groups. In addition, Camuzcuoglu et al
[18] also revealed an inverse correlation between ARE and PON
activities and the stage, grade, and CA-125 levels of patients with
ovarian cancer. In the present study, we found no correlation be-
tween esterase activities and those parameters.
The main difference between our study and that of Camuzcou-
glu et al [18] is the distribution of stages in the ovarian cancer
group. In the Camuzcuoglu et al [18] study, >60% of patients wereCamuzcuoglu et al [19]
rom controls Lower than in controls
benign ovarian tumors Not compared to benign ovarian tumors
rom healthy controls Lower than in controls
n tumor patients Not compared to benign ovarian tumors
ip Inversely correlated
ip Inversely correlated
ip Inversely correlated
ip Inversely correlated
37.5%
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>60% of patients were diagnosed with advanced ovarian cancer.
The comparison of our study and that of Camuzcuoglu et al [18] is
summarized in Table 4. In a study of PON gene single nucleotide
polymorphisms, Lurie et al [19] conﬁrmed the role of PON activity
in the pathogenesis of ovarian cancer. They showed that the
rs854560 T allele compared with the AA genotype and the rs662 A
allele compared with the GG genotype were associated with a
lower ovarian cancer risk. Furthermore, those associations were
stronger among smokers and obese women. ARE and PON activities
were also studied in the sera from patients with other types of
cancer, including gynecological malignancies. Arioz et al [20] found
signiﬁcantly lower ARE and PON activities in the sera of patients
with endometrial cancer than in healthy controls. In the study by
Elkiran et al [7], lower ARE and PON activities and a decreased
PON:ARE ratio were shown in sera from patients with lung cancer
compared to those in controls. Similarly, serum PON was lower in
patients with pancreatic [8], gastric [9], gastroesophageal [3], and
brain cancers [10].
The strengths of this study are its comparison of esterase ac-
tivities among the following three groups: patients with malignant
ovarian cancer, those with benign ovarian tumors, and healthy
controls. The groups were matched by age, BMI, and menopausal
status. Moreover, the distribution of ovarian cancer stage corre-
sponded to the normal occurrence of ovarian cancer. The main
weakness of this study is the small number of patients.
In conclusion, we found higher ARE activity in patients with
ovarian cancer than in patients with benign ovarian tumors.
However, the serum activity of ARE is similar between patients
with cancer and healthy women. Furthermore, there is no differ-
ence in PON activity and the PON:ARE activity ratio in the sera of
patients with ovarian cancer, those with benign ovarian tumors,
and healthy female controls. Serum esterase activity in patients
with benign ovarian tumors is affected by tumor size.Conﬂicts of interest
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